We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Oramed Pharmaceuticals Inc | NASDAQ:ORMP | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.005 | 0.21% | 2.35 | 2.17 | 3.73 | 2.45 | 2.35 | 2.38 | 64,697 | 05:00:10 |
ORAMED PHARMACEUTICALS INC.
|
(Exact name of registrant as specified in its charter)
|
DELAWARE
|
001-35813
|
98-0376008
|
(State or Other Jurisdiction
|
(Commission
|
(IRS Employer
|
of Incorporation)
|
File Number)
|
Identification No.)
|
Hi-Tech Park 2/4 Givat Ram, PO Box 39098, Jerusalem, Israel
|
91390
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
|
(d)
|
Exhibits.
|
99.1
|
Corporate Presentation
|
ORAMED PHARMACEUTICALS INC.
|
|||
By: |
/s/ Nadav Kidron
|
||
Name: |
Nadav Kidron
|
||
Title: |
President and CEO
|
Fasting CGM
Glucose - mg/DL (1)
|
Placebo (n = 10)
|
ORMD-0801
8 mg + 8mg (n=10)
|
Difference
(ORMD 0801 - placebo)
|
ORMD-0801
8 mg + 16mg (n=8)
|
Difference
(ORMD 0801-placebo)
|
Last 2 days of data
|
156.26 (58.62)
|
126.02 (27.26)
|
-30.24
|
136.12 (43.17)
|
-20.14
|
All 7 days
|
154.37 (57.99)
|
129.27 (27.43)
|
-25.10
|
144.83 (39.28)
|
-9.54
|
Night time mean (SD)
CGM Glucose - mg/DL(1)
|
Placebo (n = 10)
|
ORMD 0801
8 mg + 8 mg (n = 10)
|
Difference
(ORMD 0801-placebo)
|
ORMD 0801
8 mg + 16 mg (n = 8)
|
Difference (ORMD
0801 - placebo) |
Last 2 days of data
|
167.95 (64.17)
|
135.64 (39.40)
|
-32.31
|
150.24 (49.26)
|
-17.71
|
All 7 days
|
165.85 (60.76)
|
139.73 (38.86)
|
-26.12
|
149.38 (38.25)
|
-16.47
|
Daytime mean (SD)
CGM Glucose - mg/DL (1)
|
Placebo (n = 10)
|
ORMD 0801
8 mg + 8 mg (n = 10)
|
Difference
(ORMD 0801 - placebo)
|
ORMD 0801
8 mg + 16 mg (n = 8)
|
Difference (ORMD
0801-placebo) |
Last 2 days of data
|
176.06 (63.70)
|
153.23 (40.16)
|
-22.83
|
158.58 (40.67)
|
-17.48
|
All 7 days
|
175.99 (61.12)
|
152.55 (36.99)
|
-23.44
|
163.05 (30.28)
|
-12.94
|
|
|
Phase I
|
Phase II
|
Phase III
|
Timeline
|
ORMD-0801
oral insulin
|
Type 2 diabetes
|
|
Q4, ‘13: Phase IIa completed
Q4, ’14: Phase IIb multi-center study projected
initiation |
||
Type 1 diabetes
|
|
Q3, ’14: Phase IIa completed
|
|||
ORMD-0901
oral GLP-1
|
Type 2 diabetes
|
|
|
|
Q3, ’14: Preclinical/IND studies projected initiation
Q1, ’15: Phase Ib ex-US study projected initiation
Q4, ’15: Phase II multi-center study projected
initiation |
1 Year Oramed Pharmaceuticals Chart |
1 Month Oramed Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions